Bausch + Lomb Corporation BLCO
19.99 USD +0.07 (+0.35%)
At closeNov 6, 2026, 4:00 PM EST
19.99 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
19.52 Day range 20.08
14.56 52-week range 20.60
- YTD
- +17.04%
- 1 year
- +28.72%
News
seekingalpha.com Bausch + Lomb: Profits Return In Q3 As A Recovery Story, While Pipeline Grows Bausch + Lomb is rated a buy, driven by a robust pipeline, revenue growth, and a recent return to profitability. All three business segments posted Q3 revenue growth, with total revenue up 7%…
zacks.com Midterm Election Rally: 5 Relative Price Strength Stocks to Buy REPYY, BLCO, BOOM, ULH and MEOH stand out as relative price strength picks amid a post-midterm rally, backed by solid fundamentals and upbeat earnings estimates.
zacks.com Best Growth Stocks to Buy for November 5th BLCO, VLO, and HAS it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 5, 2026.
fool.com Bausch + Lomb: 3 Key Takeaways for Long-Term Investors Revenue grew 8% on a constant currency basis to $1.375 billion. Net leverage ratio fell from 5.7 times to 4.1 times.
zacks.com Why Bausch + Lomb (BLCO) Might be Well Poised for a Surge Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com Why Bausch + Lomb (BLCO) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com BLCO vs. HQY: Which Stock Is the Better Value Option? Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
zacks.com Best Momentum Stock to Buy for November 2nd ENTG, CNXN and BLCO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 2, 2026.
zacks.com Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
benzinga.com This Coinbase Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Analysts downgraded PFSI, CAMT, BLCO, COIN and FMNB; targets fell for PFSI, CAMT and COIN but rose for BLCO.
zacks.com New Strong Buy Stocks for November 2nd YPF, PBR, BLCO, LFUS and VRT have been added to the Zacks Rank #1 (Strong Buy) List on November 2, 2026.
benzinga.com HC Wainwright & Co. Downgrades Bausch & Lomb to Neutral, Raises Price Target to $22 HC Wainwright & Co. analyst Yi Chen downgrades Bausch & Lomb (NYSE:BLCO) from Buy to Neutral and raises the price target from $21 to $22.
benzinga.com JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $22 JP Morgan analyst Robbie Marcus maintains Bausch & Lomb (NYSE:BLCO) with a Neutral and raises the price target from $16 to $22.- benzinga.com RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23 RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target from $21 to $23.
benzinga.com Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19 Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target from $18 to $19.
benzinga.com Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B Estimate Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.22 by 54.55 percent. This is a 88.89 percent increase over earnings of $0.18…
benzinga.com Bausch & Lomb Raises FY2026 Sales Guidance from $5.440B-$5.540B to $5.450B-$5.550B vs $5.496B Est Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.440 billion-$5.540 billion to $5.450 billion-$5.550 billion vs $5.496 billion estimate.
benzinga.com Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up Dan Loeb’s Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.
benzinga.com Why Is Bausch + Lomb Stock Falling Monday? Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
benzinga.com Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1…
benzinga.com ‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO) amid governance concerns.
benzinga.com Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24 Leerink Partners analyst Daniel Clark initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $24.- benzinga.com HC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Maintains $21 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $21 price target.
benzinga.com Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
benzinga.com Carl Icahn Trims JetBlue, AEP Stakes While Sitting Out New Stock Bets Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power. The rest of his portfolio is unchanged.- benzinga.com HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $21 HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price target from $20 to $21.
benzinga.com UBS Maintains Buy on Bausch & Lomb, Raises Price Target to $23 UBS analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price target from $21 to $23.- benzinga.com Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 128.57 percent increase over earnings of $0.07…
- benzinga.com Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B Est Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.440 billion-$5.540 billion vs $5.468 billion estimate.
benzinga.com UBS Initiates Coverage On Bausch & Lomb with Buy Rating, Announces Price Target of $21 UBS analyst Patrick Wood initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Buy rating and announces Price Target of $21.- benzinga.com Bausch + Lomb Announces U.S. Launch Of EyeGility Inserter Preloaded IOL Delivery System EyeGility is designed for the enVista® family of IOLsOffers balanced push force for smooth delivery, convenient one-handed operationAvailable now for enVista Aspire™; will be available for enVista…
benzinga.com Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a sustained-release GA implant.
benzinga.com Bausch + Lomb Announces Phase 2 Topline Results For BL1107 In Glaucoma; Study Did Not Meet Primary Endpoint Of Replicating Earlier Visual Gains, And Company Will Discontinue Development As Topical Eye Drop Phase 2 study did not meet its primary endpoint.Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the…- benzinga.com Bausch + Lomb Creates Orphia, New AI-Powered Digital Health Platform Designed to reduce the operational burden that stands between physicians and their patients.Initial offering focuses on pre-surgery cataract education, with additional AI capabilities for…
- benzinga.com Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $17 Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and raises the price target from $16 to $17.
- benzinga.com Evercore ISI Group Maintains In-Line on Bausch & Lomb, Lowers Price Target to $16 Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and lowers the price target from $17 to $16.
- benzinga.com Bausch & Lomb Raises FY2026 Sales Guidance from $5.375B-$5.475B to $5.420B-$5.520B vs $5.436B Est Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.375 billion-$5.475 billion to $5.420 billion-$5.520 billion vs $5.436 billion estimate.
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com Bausch & Lomb Q1 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $1.244B Beat $1.218B Estimate Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 214.29 percent increase over losses of $(0.07)…
- benzinga.com Bausch + Lomb Announces European Commercial Availability Of Preloaded enVista Envy Full Range Of Vision Intraocular Lens enVista Envy is the first diffractive premium IOL from Bausch + Lomb available in EuropeOffers a continuous range of vision with excellent dysphotopsia toleranceEyeGility™ delivery system contributes…
- benzinga.com Evercore ISI Group Maintains In-Line on Bausch & Lomb, Lowers Price Target to $17 Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and lowers the price target from $17.5 to $17.
- benzinga.com Bausch + Lomb To Highlight Results Of Studies Evaluating Portfolio Of Products, Including ELIOS MIGS System, enVista Envy Full Visual Range And enVista Aspire IOLs, MIEBO, ScoutPro Point-Of-Care Osmolarity Testing Device, Stellaris Elite Vision Enhancement System, TENEO Excimer Laser Platform And XIIDRA 5% At ASCRS Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Bausch + Lomb Announces 24-Month Results From Pivotal US Trial of ELIOS System For Elevated Intraocular Pressure In Open Angle Glaucoma Patients, Meeting Primary Effectiveness Endpoints In the prospective, multicenter study, investigators at 20 sites across the U.S. enrolled 318 patients taking glaucoma medications. Patients were previously diagnosed with mild to moderate primary…
- benzinga.com Earnings Scheduled For February 18, 2026
benzinga.com Earnings Scheduled For October 29, 2025 - benzinga.com Earnings Scheduled For July 30, 2025
benzinga.com Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.
benzinga.com Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90% Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.- benzinga.com Earnings Scheduled For April 30, 2025